Back to Search Start Over

Holography-guided procedural planning for modifying Venus P -valve implantation technique in patients with left pulmonary artery stents: a case-series.

Authors :
d'Aiello AF
Schianchi L
Bevilacqua F
Ferrero P
Micheletti A
Negura DG
Pasqualin G
Chessa M
Source :
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2024 May 13; Vol. 11, pp. 1378924. Date of Electronic Publication: 2024 May 13 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Venus P -valve™ (Venus Medtech, Hangzhou, China) is a self-expandable bioprosthetic valve that can be transcatheter-implanted in native right ventricular outflow tract (RVOT) patients. Valve implantation is technically challenging. Due to the implantation technique, left pulmonary artery (LPA) stents represent a relative contraindication to Venus P -valve. In this case series, we describe our experience in implanting Venus P -valve in patients with previous LPA stents and the use of holographic models to facilitate procedural planning.<br />Methods and Results: From January to October 2023, 17 patients were scheduled for Venus P -Valve implantation. 16/17 (94%) patients were successfully implanted. 3/16 (18.7%) patients underwent Venus P -valve implantation with LPA stents. All patients underwent pre-operative CT scan. CT data set were employed to create three-dimensional (3D) holographic models (Artiness, Milan, Italy) of the entire heart, which were useful to plan valve implantation with a modified technique. Procedural success rate was 100%. No procedural complications occurred. All three patients presented good haemodynamic and angiographic results at discharge and follow-up visits.<br />Conclusion: This case-series underscores the feasibility of Venus P -valve implantation in patients with previous LPA stents. The use of holographic models facilitated procedural planning in these challenging anatomical scenarios.<br />Competing Interests: MC and Ad’A would like to declare a proctorship for Medtech Europe. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (© 2024 d'Aiello, Schianchi, Bevilacqua, Ferrero, Micheletti, Negura, Pasqualin and Chessa.)

Details

Language :
English
ISSN :
2297-055X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in cardiovascular medicine
Publication Type :
Report
Accession number :
38803661
Full Text :
https://doi.org/10.3389/fcvm.2024.1378924